Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of "Hold" from Brokerages

Key Points

• Analysts have a consensus “Hold” rating on Zentalis Pharmaceuticals, with one sell, four hold, and four buy recommendations. The average 12-month price target is $6.75, though recent targets range from $8 to $11.
• Zentalis shares opened at $3.56, with a market capitalization of approximately $255 million and a 52-week range of $1.21 to $6.95. The company reported quarterly EPS of $(0.59), missing the $(0.49) analyst consensus.
• Institutional interest has increased, with BlackRock and 5AM Venture Management taking new positions and Millennium Management expanding its stake. Zentalis is a clinical-stage oncology company developing small-molecule cancer treatments, including its lead candidate ZN-c3.

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) has been assigned a consensus recommendation of "Hold" from the nine analysts that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $6.75.

A number of equities research analysts recently commented on the company. Wall Street Zen downgraded Zentalis Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 8th. Mizuho assumed coverage on Zentalis Pharmaceuticals in a report on Friday, July 17th. They set an "outperform" rating and a $8.00 price target for the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Zentalis Pharmaceuticals in a research note on Monday, July 6th. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Friday, May 22nd. Finally, Rodman & Renshaw started coverage on Zentalis Pharmaceuticals in a report on Thursday, July 23rd. They set a "buy" rating and a $11.00 price objective on the stock.

Zentalis Pharmaceuticals Stock Performance

Shares of NASDAQ ZNTL opened at $3.56 on Friday. The company has a market cap of $255.15 million, a P/E ratio of -1.83 and a beta of 1.92. Zentalis Pharmaceuticals has a 52-week low of $1.21 and a 52-week high of $6.95. The firm's fifty day moving average is $4.34 and its two-hundred day moving average is $3.63.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.10). As a group, analysts forecast that Zentalis Pharmaceuticals will post -2.14 EPS for the current fiscal year.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several large investors have recently bought and sold shares of ZNTL. 5AM Venture Management LLC bought a new position in Zentalis Pharmaceuticals during the second quarter valued at $19,147,378,000. BlackRock Inc. purchased a new position in shares of Zentalis Pharmaceuticals in the 2nd quarter worth $18,205,000. Millennium Management LLC grew its stake in shares of Zentalis Pharmaceuticals by 220.6% in the 1st quarter. Millennium Management LLC now owns 3,069,514 shares of the company's stock worth $4,881,000 after buying an additional 2,111,951 shares in the last quarter. Ishara Investments LP bought a new stake in shares of Zentalis Pharmaceuticals in the 4th quarter worth about $1,782,000. Finally, Opaleye Management Inc. increased its holdings in shares of Zentalis Pharmaceuticals by 342.6% in the 4th quarter. Opaleye Management Inc. now owns 1,400,906 shares of the company's stock worth $1,891,000 after buying an additional 1,084,356 shares during the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis' research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company's lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source